Dilaforette appoints new VP of Development
STOCKHOLM – 8th February, 2016. Dilaforette AB, a Karolinska Development (STO:KDEV) portfolio company focused on innovative treatments for patients with sickle-cell disease, announces the appointment of Lena Jendberg as its new Vice President of Development.
Lena Jendberg joins Dilaforette from Swedish Orphan Biovitrum AB (Sobi), where she was Global Program Director, Project & Portfolio Management and Strategic Operations from 2010. In this role she was primarily responsible for Life Cycle Management of one of Sobi’s key products Kineret (anakinra) – a drug used for home treatment by patients suffering from RA or Neonatal Onset Multisystem Inflammatory Disease. Prior to this she was Program Director of Hemophilia at Biovitrum.
Lena holds an MSc in Chemical Engineering and PhD in Biochemistry/Biotechnology from the Royal Institute of Technology, KTH, Stockholm.
Lena said: “I am excited to join the Dilaforette team, and look forward to contributing to the company’s continued success as we proceed with the clinical development of our lead candidate sevuparin, which we believe can become an important treatment for the vaso-occlusive crises experienced by Sickle Cell Disease patients.”
Christina Herder, CEO of Dilaforette, said: “We are pleased to welcome Lena to the company at this exciting time. Lena brings to Dilaforette strong cross functional leadership from research to commercialization, based on her extensive knowledge of drug development gained from more than 15 years of experience.”
Dilaforette is currently enrolling SCD patients into a multi-centre, international, randomised Phase II study in Europe and the Middle East. Results from this Phase II trial with sevuparin are expected in the second half of 2016.
For further information, please contact:
Christina Herder, CEO:
Tel: +46 70 374 71 56
David Dible/ Pip Batty, Citigate Dewe Rogerson
Tel: +44 20 7638 9571
TO THE EDITORS
About Dilaforette AB
Dilaforette is a Swedish biotech company developing sevuparin - a new drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe. Sickle Cell Disease patients’ blood cells form a sickled shape, which makes blood flow to vital organs difficult, causing severe pain and even premature death. Sevuparin has the potential to improve the SCD patients’ blood flow reducing their pain for patients and the amount of time they will need to spend in hospital. Dilaforette plans to develop a formulation of sevuparin that the patient can self-administer allowing them to live a more normal life by preventing the painful episodes that result in them being hospitalised.
Dilaforette is predominantly owned by KDev Investments AB, part of Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital. Other larger owners are The Foundation for Baltic and European Studies (Östersjöstiftelsen) and Praktikerinvest AB. For more information, please visit www.dilaforette.se
Sevuparin is an innovative, proprietary polysaccharide drug, which has the potential to restore blood flow and prevent further microvascular obstructions, caused by abnormal blood cells in SCD patients. With its anti-adhesive properties, sevuparin could thereby offer treatment of the underlying cause of vaso-occlusive crisis (VOC) in SCD patients, with earlier pain relief, shorter hospital stay, reduced need of opioids and improved quality of life. Dilaforette is currently enrolling patients in a Phase II study with the aim to present data during second half of 2016.